Optimizing ASCVD Prevention Through Combination Therapy and Managing Statin Intolerance

In 'Optimizing ASCVD Prevention Through Combination Therapy and Managing Statin Intolerance,' our experts delve into the evolving lipid-lowering treatment landscape and how the availability of newer therapies is reshaping clinical decision-making for high and very high-risk patients. The panel describes an approach that begins with statin initiation while proactively counseling patients that monotherapy alone may be insufficient to reach LDL targets of less than 55 mg/dL or less than 70 mg/dL, depending on risk category. Ezetimibe is highlighted as an accessible, well-tolerated, and cost-effective oral add-on therapy that typically represents the logical next step, with PCSK9 inhibitors and other emerging agents available for patients who remain significantly above goal. The panelists emphasize the importance of continued lipid panel monitoring to guide sequential escalation rather than delaying combination therapy.

The discussion then turns to statin intolerance, with the panel distinguishing between patients who have clearly failed multiple statin trials and those experiencing manageable or context-dependent side effects such as exercise-related muscle complaints. For confirmed statin-intolerant patients, the panel supports moving directly to alternative therapies, while also exploring the potential to reintroduce very low dose or alternate-day statin regimens alongside other agents. The panelists underscore the importance of listening to patients whose quality of life is affected by perceived side effects, regardless of whether a clear physiological cause is identified. The episode closes by highlighting the pharmacological synergy of combining statins with PCSK9 inhibitors, noting that statins upregulate LDL receptors while PCSK9 inhibitors extend their lifespan, producing an additive benefit that makes combination therapy particularly powerful in patients requiring the lowest LDL targets.

Our next episode, 'The Role of Non-Statin Oral Therapies in ASCVD Risk Reduction,' further explores ASCVD, highlighting the clinical utility of ezetimibe and other non-statin oral agents as both adjunctive and alternative lipid-lowering strategies, and examining how the concept of statin reluctance is reshaping treatment sequencing for patients who are unwilling or unable to take statins.